Initially, when we thought about left atrial appendage occlusion, it was a very good idea taking into account that most thrombi are formed in left atrial appendages, about 90%. So the idea was, if we exclude left atrial appendages, we can decrease the number of thrombi that are formed. So that can fix the problem, right? If a patient’s atrial fibrillation cannot be anticoagulated, maybe this is a good alternative...
Initially, when we thought about left atrial appendage occlusion, it was a very good idea taking into account that most thrombi are formed in left atrial appendages, about 90%. So the idea was, if we exclude left atrial appendages, we can decrease the number of thrombi that are formed. So that can fix the problem, right? If a patient’s atrial fibrillation cannot be anticoagulated, maybe this is a good alternative. Actually, you don’t really have data from clinical trials that have actually shown this, that this is true. There’s a clinical trial, CLOSURE-AF, that included patients with a very high risk of bleeding, but those patients could be anticoagulated. 85% of patients actually were anticoagulated. So actually, we did not adopt the data from clinical trials. There’s a registry that was done by Professor David Werring, which included patients that had microbleeds or previous endocrine hemorrhage, and he didn’t want to use anticoagulants. And he showed in this registry, that’s mainly observational data, right, that it’s possible to perform it and it was not associated with an increased number of events, either ischemic events or hemorrhagic events. So it’s something that you can propose to the patient, but you have to tell him that there’s very little data actually at the moment that proves that this procedure can actually show a clear benefit. Also, another thing that you have to take into account, because it is still an invasive procedure, you have to take into account what’s the patient’s life expectancy. So what some of the data that we have from culture, for example, has shown that those patients, because they have increased frailty or also have a higher probability of dying from concurrent diseases, right? So you have to take into account actually what’s the life expectancy of the patient, see the patient himself, what are his characteristics, and also explain to him that we don’t have clear data, that’s a possible intervention that you can do in that.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.